233 related articles for article (PubMed ID: 23749327)
1. Guidelines for biomarker testing in gastroenteropancreatic neuroendocrine neoplasms: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
García-Carbonero R; Vilardell F; Jiménez-Fonseca P; González-Campora R; González E; Cuatrecasas M; Capdevila J; Aranda I; Barriuso J; Matías-Guiu X; ;
Clin Transl Oncol; 2014 Mar; 16(3):243-56. PubMed ID: 23749327
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): what's better?
Milione M
Endocrine; 2018 Jan; 59(1):1-3. PubMed ID: 28417314
[No Abstract] [Full Text] [Related]
3. GEP-NETs UPDATE: Secreting gastro-enteropancreatic neuroendocrine tumours and biomarkers.
Verbeek WH; Korse CM; Tesselaar ME
Eur J Endocrinol; 2016 Jan; 174(1):R1-7. PubMed ID: 26162406
[TBL] [Abstract][Full Text] [Related]
4. [Consensus and controversy of endoscopic diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors].
Chen H; Chen Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):982-986. PubMed ID: 28900987
[TBL] [Abstract][Full Text] [Related]
5. Workup of Gastroenteropancreatic Neuroendocrine Tumors.
Dillon JS
Surg Oncol Clin N Am; 2020 Apr; 29(2):165-183. PubMed ID: 32151354
[TBL] [Abstract][Full Text] [Related]
6. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
[TBL] [Abstract][Full Text] [Related]
7. Biochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine Tumors.
Maxwell JE; O'Dorisio TM; Howe JR
Surg Oncol Clin N Am; 2016 Jan; 25(1):171-94. PubMed ID: 26610781
[TBL] [Abstract][Full Text] [Related]
8. Gastroenteropancreatic Neuroendocrine Tumors.
Cives M; Strosberg JR
CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
[TBL] [Abstract][Full Text] [Related]
9. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas.
Garcia-Carbonero R; Sorbye H; Baudin E; Raymond E; Wiedenmann B; Niederle B; Sedlackova E; Toumpanakis C; Anlauf M; Cwikla JB; Caplin M; O'Toole D; Perren A;
Neuroendocrinology; 2016; 103(2):186-94. PubMed ID: 26731334
[No Abstract] [Full Text] [Related]
10. Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors.
Bellizzi AM
Surg Oncol Clin N Am; 2020 Apr; 29(2):185-208. PubMed ID: 32151355
[TBL] [Abstract][Full Text] [Related]
11. [Diagnosis for the gastroenteropancreatic neuroendocrine tumors].
Komoto I; Imamura M
Nihon Shokakibyo Gakkai Zasshi; 2014 Dec; 111(12):2263-71. PubMed ID: 25482901
[No Abstract] [Full Text] [Related]
12. Somatostatin receptor immunohistochemistry in neuroendocrine tumors: comparison between manual and automated evaluation.
Kaemmerer D; Athelogou M; Lupp A; Lenhardt I; Schulz S; Luisa P; Hommann M; Prasad V; Binnig G; Baum RP
Int J Clin Exp Pathol; 2014; 7(8):4971-80. PubMed ID: 25197368
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
14. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
Shi H; Zhang Q; Han C; Zhen D; Lin R
BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
[TBL] [Abstract][Full Text] [Related]
15. The ultimate biochemical diagnosis of neuroendocrine gastro-enteropancreatic tumours.
Faiss S; Scherübl H; Riecken EO; Wiedenmann B
Digestion; 1996; 57 Suppl 1():48-9. PubMed ID: 8813469
[TBL] [Abstract][Full Text] [Related]
16. Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
Kanakis G; Kaltsas G
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):791-802. PubMed ID: 23582919
[TBL] [Abstract][Full Text] [Related]
17. Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.
Kaemmerer D; Peter L; Lupp A; Schulz S; Sänger J; Prasad V; Kulkarni H; Haugvik SP; Hommann M; Baum RP
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1659-68. PubMed ID: 21626438
[TBL] [Abstract][Full Text] [Related]
18. Role of biomarker tests for diagnosis of neuroendocrine tumours.
Hofland J; Zandee WT; de Herder WW
Nat Rev Endocrinol; 2018 Nov; 14(11):656-669. PubMed ID: 30158549
[TBL] [Abstract][Full Text] [Related]
19. c-MET inhibition: novel treatment for sporadic and MEN1-associated GEP NETs.
Lee ME; Tepede AA; Mandl A; Weinstein LS; Del Rivero J; Agarwal SK; Blau JE
J Mol Endocrinol; 2020 Aug; 65(2):R1-R17. PubMed ID: 32384260
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic well-differentiated neuroendocrine neoplasms (pWDNENs): what place for everolimus and sunitinib derived from ESMO clinical practice guidelines in the therapeutic algorithm?
Pusceddu S; Buzzoni R; De Braud F
Ann Oncol; 2013 May; 24(5):1415-6. PubMed ID: 23493138
[No Abstract] [Full Text] [Related]
[Next] [New Search]
